Orbital Therapeutics: Valuation, Funding & Investors
Orbital Therapeutics is an early-stage biotechnology company focused on developing RNA-based medicines. Founded in 2022, the company is advancing its lead program, OTX-201, a potential in vivo CAR T treatment for autoimmune conditions that uses lipid nanoparticles to deliver RNA into patient cells. This innovative approach aims to enable the body to produce targeted T cells to combat disease, with the treatment currently in preclinical stages.
Leadership & Board
Key Executives
- Chief Financial Officer
- Terry-Ann Burrell
- Co-Founder and Chairman
- Peter Barrett
- Chief Operating Officer
- Gillian Ivers-Read
- President and Chief Scientific Officer
- Giuseppe Ciaramella
- Co-Founder
- Nathaniel Brooks Horwitz
- Current Number of Employees
- 9
- Current LinkedIn Followers
- 18,397
Latest Estimated Valuation
- Total Amount Raised
- $270M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $270M
- Latest Funding Round
- Series A
Employee Trend
Orbital Therapeutics had 9 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Orbital Therapeutics had 18,397 followers as of November 16, 2026. The number of followers increased by 5 (0.03%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Oct 10, 2025 | Series A | $270.00M | ― |
Similar Companies
A snapshot of private companies similar to Orbital Therapeutics, helping you discover and navigate related company profiles.








